An international research team has developed two inexpensive and simple blood tests to aid in the diagnosis of hepatitis B patients living in underprivileged African regions and are requiring treatment.

Researchers from Imperial College London, Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, and the Pasteur Institute in Paris collaborated with additional African and European institutions to develop an accurate diagnostic score called TREAT-B.

The score comprises two blood tests for the precise identification of individuals who urgently need treatment for the hepatitis B virus infection.

“While the test is yet to be assessed in larger studies, it is expected to help thousands of patients who need life-saving treatment.”

One blood test is designed to detect the presence of antigens generated by the virus, while the second test measures enzymes produced by the liver in response to these antigens.

Upon evaluation, the researchers observed that the score is similar in accuracy to current approaches to identify patients requiring immediate treatment. It is said to cost $20.

Imperial College London Department of Surgery & Cancer researcher Dr Maud Lemoine said: “These results show that this simple and inexpensive test could be an accurate way to diagnose patients in need of hepatitis B treatment in countries with limited resources.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This could potentially help diagnose and subsequently treat thousands of people across Africa.”

The TREAT-B score was developed using data from more than 800 hepatitis B patients under the PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) study.

To validate the tests, the team used data from African patients in Senegal, Burkina Faso, Germany, France and the UK. The score was found to be 85% accurate in identifying HBV positive patients requiring treatment and 77% in detecting those who do not need treatment.

While the test is yet to be assessed in larger studies, it is expected to help thousands of patients who need life-saving treatment.

The researchers plan to further develop TREAT-B as a finger-prick test in order to enable faster results.